Compare MFC & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MFC | EW |
|---|---|---|
| Founded | 1887 | 1958 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.8B | 45.5B |
| IPO Year | 1999 | 2000 |
| Metric | MFC | EW |
|---|---|---|
| Price | $36.53 | $86.65 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 20 |
| Target Price | $52.00 | ★ $95.83 |
| AVG Volume (30 Days) | 2.5M | ★ 3.5M |
| Earning Date | 11-12-2025 | 02-10-2026 |
| Dividend Yield | ★ 3.42% | N/A |
| EPS Growth | ★ 10.85 | N/A |
| EPS | 2.24 | ★ 2.33 |
| Revenue | ★ $22,912,074,891.00 | $5,883,800,000.00 |
| Revenue This Year | $34.60 | $14.26 |
| Revenue Next Year | $8.50 | $9.77 |
| P/E Ratio | ★ $16.28 | $37.85 |
| Revenue Growth | 6.09 | ★ 10.60 |
| 52 Week Low | $25.92 | $65.94 |
| 52 Week High | $36.59 | $87.89 |
| Indicator | MFC | EW |
|---|---|---|
| Relative Strength Index (RSI) | 70.59 | 59.50 |
| Support Level | $35.56 | $84.64 |
| Resistance Level | $35.61 | $86.19 |
| Average True Range (ATR) | 0.46 | 1.73 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 95.48 | 77.48 |
Manulife Financial is one of the Big Three Canadian life insurers. The firm provides life insurance, annuities, asset management, and wealth management products to individuals and group customers in Canada, the United States, and Asia. The Canadian business segment contributes approximately 22% of adjusted earnings. The Asia segment operates across 12 countries and contributes around 36% of earnings, with a significant presence in Hong Kong and Singapore. The US business, which primarily operates under the John Hancock brand, contributes about 23% of earnings. Manulife's global asset and wealth management business contributes approximately 20% of its earnings and had around CAD 1.03 trillion in assets under management and administration as of the end of 2024.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.